Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Agilon Health Inc’s stock clocked out at $0.7, up 2.04% from its previous closing price of $0.69. In other words, the price has increased by $2.04 from its previous closing price. On the day, 1.86 million shares were traded. AGL stock price reached its highest trading level at $0.7089 during the session, while it also had its lowest trading level at $0.6753.
Ratios:
To gain a deeper understanding of AGL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.08 and its Current Ratio is at 1.08. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 06, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $1.
Citigroup Upgraded its Neutral to Buy on April 25, 2025, while the target price for the stock was maintained at $5.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 290621696 and an Enterprise Value of 16888704. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.05 while its Price-to-Book (P/B) ratio in mrq is 0.95. Its current Enterprise Value per Revenue stands at 0.003 whereas that against EBITDA is -0.049.
Stock Price History:
The Beta on a monthly basis for AGL is 0.06, which has changed by -0.6310526 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, AGL has reached a high of $6.08, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is -4.02%, while the 200-Day Moving Average is calculated to be -65.20%.
Shares Statistics:
It appears that AGL traded 9.02M shares on average per day over the past three months and 6216780 shares per day over the past ten days. A total of 414.57M shares are outstanding, with a floating share count of 304.83M. Insiders hold about 26.47% of the company’s shares, while institutions hold 68.69% stake in the company. Shares short for AGL as of 1765756800 were 20639623 with a Short Ratio of 2.29, compared to 1763078400 on 20803215. Therefore, it implies a Short% of Shares Outstanding of 20639623 and a Short% of Float of 8.140001.
Earnings Estimates
As of right now, 8.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.04, with high estimates of $0.02 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.59 and -$0.85 for the fiscal current year, implying an average EPS of -$0.74. EPS for the following year is -$0.42, with 12.0 analysts recommending between -$0.33 and -$0.52.
Revenue Estimates
In. The current quarter, 14 analysts expect revenue to total $1.46B. It ranges from a high estimate of $1.54B to a low estimate of $1.42B. As of. The current estimate, Agilon Health Inc’s year-ago sales were $1.52BFor the next quarter, 14 analysts are estimating revenue of $1.59B. There is a high estimate of $1.67B for the next quarter, whereas the lowest estimate is $1.5B.
A total of 16 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $5.9B, while the lowest revenue estimate was $5.78B, resulting in an average revenue estimate of $5.82B. In the same quarter a year ago, actual revenue was $6.06BBased on 16 analysts’ estimates, the company’s revenue will be $6.01B in the next fiscal year. The high estimate is $6.41B and the low estimate is $5.51B.
